November 16, 2018 05:37 AM EST

AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival

ENDPOINTS

Last year, AstraZeneca preached patience after initial data showed its checkpoint inhibitor Imfinzi combined with their in-house CTLA-4 drug failed to meet the primary endpoint …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As­traZeneca’s big MYS­TIC tri­al ends a com­plete fail­ure as Imfinzi/treme­li­mum­ab com­bo flops on over­all sur­vival

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival